Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Initiates Phase 2 Study of MOR208 in NHL

Published: Monday, May 13, 2013
Last Updated: Monday, May 13, 2013
Bookmark and Share
Company has dosed the first patient in Phase 2 clinical trial of anti-CD19 antibody.

MorphoSys AG has announced that it has dosed the first patient in a Phase 2 clinical trial of MOR208 in Non-Hodgkin's Lymphoma (NHL).

MOR208 is a potent Fc-optimized anti-CD19 antibody to which MorphoSys gained worldwide rights via an exclusive license and collaboration agreement with Xencor in 2010.

The open-label, multicenter, single-arm clinical trial is designed to assess the efficacy of MOR208 in patients with relapsed or refractory Non-Hodgkin's Lymphoma.

Secondary outcome measures include response duration, safety and pharmacokinetics of MOR208. A total of up to 120 patients are planned to be enrolled in four separate sub-indications (FL, MCL, DLBCL and other forms of indolent NHL).

More information on the trial can be found by searching for MOR208 at www.clinicaltrials.gov. The trial is to be conducted at sites across both Europe and the US.

"In MOR208 we have a very exciting cancer program with a huge potential. Evaluating MOR208 in NHL and B-ALL - building on the data we already have for CLL - should enable us to assess the therapeutic benefit and broader commercial potential of the molecule in hematological malignancies," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG.

Dr. Schottelius continued, "Broadening the drug's development program into additional indications is intended to maximize the value of this compound."

MOR208 showed encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in a Phase 1/2a trial in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In addition to the phase 2 trial in NHL, MorphoSys is currently evaluating the compound in a phase 2 trial in B-cell Acute Lymphoblastic Leukemia (B-ALL).

B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and fifty thousand patients in the seven major markets each year.

The target molecule CD19 is expressed more broadly and earlier in B-cell development than CD20, the target of the marketed cancer drug Rituxan®.

Therefore targeting CD19 could potentially allow for an even broader therapeutic use of MOR208 than marketed anti-CD20 antibodies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys, MD Anderson Partner
MorphoSys AG and The University of Texas MD Anderson Cancer Center have announced a long-term strategic alliance for the discovery and development of novel therapeutic antibodies against cancer.
Wednesday, May 25, 2016
MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial
Phase 2 trial designed to support registration of anetumab ravtansine.
Wednesday, January 27, 2016
MorphoSys Presents Safety and Efficacy Data for MOR202 at ASH Meeting
MOR202 exhibits encouraging clinical activity and good safety profile with best-in-class infusion tolerability.
Tuesday, December 08, 2015
MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys Provides an Update on its Proprietary Development Portfolio
Lead cancer program MOR208 to be examined in numerous combination studies in hematological cancers.
Thursday, September 10, 2015
MorphoSys and Immatics Enter Strategic Alliance in Immuno-oncology
Collaboration aims to develop novel antibody-based therapies targeting tumor-associated peptides derived from intracellular proteins.
Tuesday, August 25, 2015
MorphoSys AG Reports Results for the First Six Months of 2015
Therapeutic pipeline exceeds 100 drug candidates in research & development.
Saturday, August 08, 2015
MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program
Successful discovery alliance combines two leading technologies.
Thursday, August 06, 2015
MorphoSys and G7 Therapeutics Sign Alliance
Collaboration broadens MorphoSys' capabilities to target novel antigen classes.
Thursday, August 06, 2015
MorphoSys Announces Clinical Milestone in Blood Disorders Program
Company has received milestone payment from Novartis.
Saturday, July 25, 2015
MorphoSys Presents Updated Phase 2 Clinical Results for MOR208
Matured data set shows six complete remissions with durable responses in diffuse large B-cell lymphoma and follicular lymphoma.
Thursday, June 04, 2015
MorphoSys Presents First Safety, Pharmacokinetic and Efficacy Data for MOR202
Clinical activity and long-lasting tumor control already observed at low doses.
Wednesday, June 03, 2015
MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA
Substantial data packages on lead compounds MOR202 and MOR208.
Tuesday, May 26, 2015
MorphoSys to Present Data on Proprietary Programs at ASCO Annual Meeting
Abstracts include first clinical data for MOR202.
Tuesday, May 26, 2015
MorphoSys AG Reports Results for the First Three Months of 2015
First quarter positively impacted by one-off effects relating to MOR202.
Tuesday, May 12, 2015
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!